Abstract:Does growth hormone (GH) supplementation during ovarian stimulation affect the euploid rate and morphokinetic characteristics of euploid embryos in patients with advanced maternal age (AMA)? GH supplementation improved the probability of obtaining euploid blastocysts in women with AMA, while did not affect the morphokinetic parameters of the euploid embryos. Studies have demonstrated that supplementation with GH during ovarian stimulation (OS) has positive impact on the clinical outcomes of in vitro fertilization (IVF). However, few studies have investigated the association of GH supplementation with the ploidy status of embryos. Meanwhile, it is unclear whether GH supplementation affects the morphokinetic signatures and the transfer outcomes of euploid blastocysts. Therefore, the underlying reason for the effect of GH on IVF outcomes remains largely unknown. This is a single centre open-labelled randomized controlled trial conducted at single IVF center from August 2022 to August 2023. A total of 441 patients were screened for eligibility and 309 patients were enrolled and allocated. The primary outcome was the proportion of cycles which obtained euploid blastocysts. Secondary outcomes included euploid blastocyst rate per cohort, euploid blastocyst rate per cycle and morphokinetic parameters of euploid embryos obtained with or without GH supplementation. A total of 309 patients aged 38–46 years who underwent their first preimplantation genetic testing for aneuploidy (PGT-A) cycle using antagonist protocol were randomized into the GH group or the control group at 1:1 ratio, with all embryos cultured in the time-lapse monitoring system. Patients in the GH group received 2 IU/day subcutaneous GH from the 2nd day of the previous menstrual period until the day of trigger, for a total of approximately 6 weeks. The baseline and cycle characteristics between the two groups were similar. The proportion of cycles which obtained euploid blastocysts was significantly higher in the GH group (44.74% vs 31.85%, p = 0.02). The GH group had a significantly higher euploid blastocyst rate per cohort (38.46% vs 28.01%, p = 0.01) and mean euploid blastocyst rate per cycle (per biopsy cycle 0.38±0.43 vs. 0.26±0.39, p = 0.02; per OS cycle 0.29±0.41 vs. 0.19±0.36, p = 0.03). Multivariate logistic regression indicated GH supplement was an independent factor for acquisition of euploid embryos (adjusted risk ratio=1.79, 95%CI [1.06-2.99], p = 0.03). We did not observe a statistically significant difference in the morphokinetic parameters and transfer outcomes of the euploid embryos acquired with or without GH supplemented. This was a single center study which limited the sample size, further limiting the number of patients with euploid blastocysts analyzed for the morphokinetic parameters and transfer outcomes. Meanwhile, affordability may also introduce selection bias since patients were required to pay for GH. Our research presents new evidence that GH supplementation AMA patients increased the probability of obtaining euploid blastocysts, and explains the underlying reason for the positive effect of GH on IVF outcomes in existing studies. The effect of GH on morphokinetic parameters and transfer outcomes of euploid embryos warrants further investigation. NCT05447208, www.clinicaltrials.gov.

Growth hormone reduces aneuploidy and improves oocytes quality by JAK2-MAPK3/1 pathway in aged mice

Growth hormone ameliorates the age-associated depletion of ovarian reserve and decline of oocyte quality via inhibiting the activation of Fos and Jun signaling

Evidence that growth hormone can improve mitochondrial function in oocytes from aged mice

Effects Of Growth Hormone Supplementation In Poor Responders Undergoing In Vitro Fertilization/Intracytoplasmic Sperm Injection Treatment

HucMSC-Derived Exosomes Mitigate the Age-Related Retardation of Fertility in Female Mice

Growth Hormone Promotes Oocyte Maturation in Vitro by Protecting Mitochondrial Function and Reducing Apoptosis

Effect of growth hormone administration on ameliorating pregnancy outcome in women with advanced maternal age and exploration of its optimized utilization

IGF2 improves the developmental competency and meiotic structure of oocytes from aged mice

Epigallocatechin-3-gallate Improves the Quality of Maternally Aged Oocytes.

Alpha-ketoglutarate supplementation ameliorates ovarian reserve and oocyte quality decline with aging in mice

Follicle-Stimulating Hormone Alleviates Ovarian Aging by Modulating Mitophagy- and Glycophagy-Based Energy Metabolism in Hens

The Effect of Growth Hormone on the IVF Outcome of the Patients of Advanced Age With Decreased Ovarian Reserve

Growth Hormone Supplementation During Ovarian Stimulation in Women with Advanced Maternal Age Undergoing Preimplantation Genetic Testing for Aneuploidy.

A direct action for GH in improvement of oocyte quality in poor-responder patients

O-157 The effect of growth hormone on the euploid rate and morphokinetic signature of blastocysts in patients with advanced maternal age : a randomized controlled trial

Growth Hormone Treatment of Premature Ovarian Failure in a Mouse Model Via Stimulation of the Notch-1 Signaling Pathway

Growth Hormone Promotes in vitro Maturation of Human Oocytes.

α‐ketoglutarate delays age‐related fertility decline in mammals

Rejuvenation of aged oocyte through exposure to young follicular microenvironment

Growth hormone alleviates oxidative stress and improves oocyte quality in Chinese women with polycystic ovary syndrome: a randomized controlled trial

Does growth hormone supplementation of in vitro fertilization/intracytoplasmic sperm injection improve cumulative live birth rates in women with poor embryonic development in the previous cycle?